Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC 50 values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 main protease . Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis.
Products | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Heart Disease | Products > Disease Areas > Hypertension | Products > Disease Areas > Heart Failure | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Calcium Channel | Products > Signaling Pathways > SARS-CoV
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。